{"id":"W4295592704","doi":"10.1016/j.esmoop.2022.100572","title":"The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report","year":2022,"lang":"en","type":"article","venue":"ESMO Open","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Eli Lilly Japan; Medtronic Japan; Chugai Pharmaceutical; Genentech; Taiho Pharmaceutical; Sanofi; GlaxoSmithKline; Teijin Pharma; Amgen; Pfizer; Les Laboratories Pierre Fabre; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Ono Pharmaceutical","keywords":"Osimertinib; Medicine; Oncology; Internal medicine; Adjuvant; Hazard ratio; Stage (stratigraphy); Lung cancer; Clinical endpoint; Adjuvant therapy; Disease; Erlotinib; Cancer; Confidence interval; Clinical trial; Epidermal growth factor receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005589168,0.0001176266,0.0002491633,0.00004352452,0.0001389072,0.00003659432,0.0003778988,0.00001943551,0.0002303463],"category_scores_gemma":[0.00006619182,0.00008605231,0.00004897514,0.00009885733,0.00006114633,0.00004936475,0.0005997185,0.0001333232,7.127713e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002481728,"about_ca_system_score_gemma":0.0005140456,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01242204,"about_ca_topic_score_gemma":0.003007049,"domain_scores_codex":[0.9987461,0.00009150684,0.0003423359,0.0003209577,0.0003311837,0.0001679277],"domain_scores_gemma":[0.9989558,0.0001456323,0.0001700601,0.0005309543,0.00006817115,0.0001293856],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001036712,0.0005491896,0.990117,0.00003938584,0.0002113714,0.00073134,0.0005285967,0.0002007414,0.00003125102,0.0004047674,0.004543324,0.001606361],"study_design_scores_gemma":[0.005732029,0.0002482843,0.9814715,0.0001580023,0.0002493587,0.00004241454,0.0006899842,0.001738815,0.0004230477,0.0001229831,0.008986719,0.00013684],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9831052,0.001126752,0.000001814552,0.008298396,0.0007186821,0.001143499,0.000145803,0.000008716198,0.005451133],"genre_scores_gemma":[0.9974947,0.0004576067,0.00009924886,0.0002918458,0.00009276744,0.0005700117,0.00007756035,0.0000202675,0.000896002],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01438949,"threshold_uncertainty_score":0.9941543,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0247869129713328,"score_gpt":0.3389535306115541,"score_spread":0.3141666176402214,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}